During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

Het wordt wereldwijd gewaardeerd vanwege zijn huidondersteunende eigenschappen en zijn populariteit binnen premium anti-aging formules
Cardiovasc Res 107(3):364372 Xu J et al (2017) Vascular CXCR206 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma
Increases mobility for people with peripheral artery disease Peripheral artery disease occurs when the peripheral arteries become clogged by plaque
Heartburn Heartburn is another uncommon yet possible side effect of semaglutide injections